Premium
Combined glycoprotein IIb/IIIa receptor inhibition and low‐dose fibrinolysis for peripheral arterial thrombosis
Author(s) -
RochaSingh Krishna J.,
Trokey Janiece
Publication year - 2002
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.10135
Subject(s) - reteplase , medicine , abciximab , fibrinolytic agent , thrombosis , streptokinase , peripheral , fibrinolysis , surgery , tissue plasminogen activator , myocardial infarction , percutaneous coronary intervention
This feasibility study evaluated the therapeutic potential of combined GP IIb/IIIa receptor inhibition with abciximab and low‐dose fibrinolysis with reteplase for treatment of acute femoropopliteal thrombosis. The simultaneous intra‐arterial administration of abciximab in conjunction with low‐dose reteplase (≤ 0.5 U/hr) was safe in 13 patients; 2 patients experienced major hemorrhagic complication at a reteplase dose of 1 U/hr. The primary success rate was 100%; all patients experienced an excellent clinical response with no clinical evidence of distal embolization. No patient required repeat endovascular or surgical revascularization during mean follow‐up of 9.3 months. This promising new thrombolytic strategy for the treatment of peripheral arterial occlusive disease requires further study. Cathet Cardiovasc Intervent 2002;55:457–460. © 2002 Wiley‐Liss, Inc.